Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ribo-SiRNA

More Like This

PR Newswire associated0

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

PR Newswire associated0

Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

PR Newswire associated0

Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs

PR Newswire associated0

Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

PR Newswire associated0

Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care

PR Newswire associated0

Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange

PR Newswire associated0

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

PR Newswire associated0

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development